Paulina Cybulska1, Jill Tseng1, Qin C Zhou2, Alexia Iasonos2,3, Deborah F Delair4,5, Jennifer J Mueller1,3, Kara C Long Roche1,3, Nadeem R Abu-Rustum1,3, Mario M Leitao1,3. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Joan & Sanford I. Weill Medical College of Cornell University, New York, New York, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 5. Department of Pathology, NYU Langone Medical Center, New York, New York, USA.
Abstract
BACKGROUND: Endometrioid epithelial ovarian cancer (EEOC) is rare, and its management poorly defined. We examined factors associated with 5-year progression-free survival (PFS) after surgery for EEOC. METHODS: Retrospective study: treatment and outcomes of all EEOC patients undergoing initial surgery at, or presenting to, our institution within 3 months of initial surgery, 1/2002-9/2017. RESULTS: In total, 212 patients were identified. Median follow-up, 63.9 months (range, 0.7-192); median age at diagnosis, 52 years (range, 20-88); disease stage: I, n = 145 (68%); II, n = 47 (22%); III/IV, n = 20 (9%); FIGO grade: 1, 127 (60%); 2, 66 (31%); 3, 17 (8%); unknown, 2 (1%). One hundred twenty-eight (60%) had endometriosis; 75 (35%), synchronous endometrioid endometrial cancer (80%, IA); 101 (48%), complete surgical staging; 8 (5%), positive pelvic lymph nodes (LNs); 6 (4%), positive para-aortic LNs; 176 (97%), complete gross resection; 123 (60%), postoperative chemotherapy; 56(28%), no additional treatment. Five-year PFS, 83% (95% confidence interval [CI]: 76.6%-87.8%); 5-year overall survival (OS), 92.7% (95% CI: 87.7%-95.8%). Age, stage, and surgical staging were associated with improved 5-year PFS, and younger age at diagnosis with improved 5-year OS (p < 0.001). Chemotherapy did not improve 5-year PFS in IA/IB versus observation, but improved survival in IC (hazard ratio [HR]: 1.01, 95% CI: 0.22-4.59, p = 0.99; HR: 0.17, 95% CI: 0.04-0.7, p = 0.006). CONCLUSIONS: Age, stage, and full surgical staging were associated with improved 5-year PFS. Chemotherapy showed no benefit in IA/IB disease.
BACKGROUND: Endometrioid epithelial ovarian cancer (EEOC) is rare, and its management poorly defined. We examined factors associated with 5-year progression-free survival (PFS) after surgery for EEOC. METHODS: Retrospective study: treatment and outcomes of all EEOC patients undergoing initial surgery at, or presenting to, our institution within 3 months of initial surgery, 1/2002-9/2017. RESULTS: In total, 212 patients were identified. Median follow-up, 63.9 months (range, 0.7-192); median age at diagnosis, 52 years (range, 20-88); disease stage: I, n = 145 (68%); II, n = 47 (22%); III/IV, n = 20 (9%); FIGO grade: 1, 127 (60%); 2, 66 (31%); 3, 17 (8%); unknown, 2 (1%). One hundred twenty-eight (60%) had endometriosis; 75 (35%), synchronous endometrioid endometrial cancer (80%, IA); 101 (48%), complete surgical staging; 8 (5%), positive pelvic lymph nodes (LNs); 6 (4%), positive para-aortic LNs; 176 (97%), complete gross resection; 123 (60%), postoperative chemotherapy; 56(28%), no additional treatment. Five-year PFS, 83% (95% confidence interval [CI]: 76.6%-87.8%); 5-year overall survival (OS), 92.7% (95% CI: 87.7%-95.8%). Age, stage, and surgical staging were associated with improved 5-year PFS, and younger age at diagnosis with improved 5-year OS (p < 0.001). Chemotherapy did not improve 5-year PFS in IA/IB versus observation, but improved survival in IC (hazard ratio [HR]: 1.01, 95% CI: 0.22-4.59, p = 0.99; HR: 0.17, 95% CI: 0.04-0.7, p = 0.006). CONCLUSIONS: Age, stage, and full surgical staging were associated with improved 5-year PFS. Chemotherapy showed no benefit in IA/IB disease.
Authors: John P Stamp; C Blake Gilks; Martine Wesseling; Sima Eshragh; Kathy Ceballos; Michael S Anglesio; Janice S Kwon; Alicia Tone; David G Huntsman; Mark S Carey Journal: Int J Gynecol Cancer Date: 2016-06 Impact factor: 3.437
Authors: Paulina Cybulska; Arnaud Da Cruz Paula; Jill Tseng; Mario M Leitao; Ali Bashashati; David G Huntsman; Tayyebeh M Nazeran; Carol Aghajanian; Nadeem R Abu-Rustum; Deborah F DeLair; Sohrab P Shah; Britta Weigelt Journal: Gynecol Oncol Date: 2019-07-21 Impact factor: 5.482
Authors: A Oseledchyk; M M Leitao; J Konner; R E O'Cearbhaill; D Zamarin; Y Sonoda; G J Gardner; K Long Roche; C A Aghajanian; R N Grisham; C L Brown; A Snyder; D S Chi; R A Soslow; N R Abu-Rustum; O Zivanovic Journal: Ann Oncol Date: 2017-12-01 Impact factor: 32.976
Authors: Dawn J Storey; Robert Rush; Moira Stewart; Tzyvia Rye; Awatif Al-Nafussi; Alistair R Williams; John F Smyth; Hani Gabra Journal: Cancer Date: 2008-05-15 Impact factor: 6.860
Authors: John K Chan; Chunqiao Tian; Gini F Fleming; Bradley J Monk; Thomas J Herzog; Daniel S Kapp; Jeffrey Bell Journal: Gynecol Oncol Date: 2009-11-28 Impact factor: 5.482
Authors: Anne M Schultheis; Charlotte K Y Ng; Maria R De Filippo; Salvatore Piscuoglio; Gabriel S Macedo; Sonia Gatius; Belen Perez Mies; Robert A Soslow; Raymond S Lim; Agnes Viale; Kety H Huberman; Jose C Palacios; Jorge S Reis-Filho; Xavier Matias-Guiu; Britta Weigelt Journal: J Natl Cancer Inst Date: 2016-02-01 Impact factor: 13.506
Authors: Pamela T Soliman; Brian M Slomovitz; Russell R Broaddus; Charlotte C Sun; Jonathan C Oh; Patricia J Eifel; David M Gershenson; Karen H Lu Journal: Gynecol Oncol Date: 2004-08 Impact factor: 5.482